Effect of CD31 Peptide on the Induction of GVHD in B10D2 → BalB/c Recipients
| Group . | n . | Incidence Day 30 . | Incidence Day 70 . | Medium Onset (d) . | Median Survival Time (d) . | % Actuarial Survival >100 Days . |
|---|---|---|---|---|---|---|
| CD31 peptide | 14 | 5/14* | 14/14 | 32 | >100 | 86† |
| PBS | 10 | 10/10 | 10/10 | 19 | 70 | 0 |
| Control peptide | 5 | 5/5 | 5/5 | 19 | 69 | 0 |
| Group . | n . | Incidence Day 30 . | Incidence Day 70 . | Medium Onset (d) . | Median Survival Time (d) . | % Actuarial Survival >100 Days . |
|---|---|---|---|---|---|---|
| CD31 peptide | 14 | 5/14* | 14/14 | 32 | >100 | 86† |
| PBS | 10 | 10/10 | 10/10 | 19 | 70 | 0 |
| Control peptide | 5 | 5/5 | 5/5 | 19 | 69 | 0 |
Lethally irradiated (8.0 Gy) BALB/c recipients were transplanted with 1.25 × 106 B10D2 bone marrow cells and 5 × 106 B10D2 spleen cells on day 0. Recipients were IP injected with CD31 peptide (100 mg/d) or with PBS or control peptide (100 mg/d) as control for the first 5 weeks.
Incidence of GVHD of recipients given CD31 peptide compared with recipients given PBS and control peptide by Fisher's exact test: P < .01.
GVHD-related mortality assessed by Mann-Whitney log-rank analysis: P = .0001 survival of recipients given CD31 peptide compared with recipients given PBS and control peptide.